全球乳癌市場規模、佔有率和成長分析：按癌症和配銷通路- 行業預測（2023-2030）

Global Breast Cancer Market Size, Share, Growth Analysis, By Cancer(Hormone Receptor-positive (HR+) and HER2-positive (HER2+)), By Distribution Channel(hospital pharmacies, retail pharmacies) - Industry Forecast 2023-2030

出版日期: 2023年10月12日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2021年全球乳癌市場規模為288.8億美元，從2022年的318.9億美元成長到2030年的705.3億美元，年複合成長率預計將成長10.43%。

全球乳癌發生率不斷上升推動了該市場的發展。生活型態的改變、荷爾蒙失衡、遺傳傾向和高齡化因素導致乳癌病例增加。患者數量的不斷增加需要開發有效且創新的治療方案和診斷工具。技術進步在市場成長中發揮重要作用。分子成像、基因檢測、液體活體組織切片等新診斷技術能夠實現乳癌的早期發現和準確診斷。同樣，包括標靶治療、免疫療法和精準治療方法在內的治療進展正在改善患者的治療結果和存活率。這些進步正在推動市場對創新產品和治療方法的需求。此外，公眾對乳癌的認知不斷提高以及早期檢測的重要性，導致人們更多地參與篩檢計劃和定期檢查。世界各地的政府和醫療機構正在進行宣傳活動，以促進早期發現，從而導致對篩檢和診斷的需求增加。儘管成長前景良好，但市場也面臨一些挑戰。主要挑戰之一是乳癌治療的高成本，包括手術、化療、放射線治療和標靶治療。患者和衛生系統的經濟負擔可能會限制獲得最佳治療方案，特別是在資源有限的環境中。

全球乳癌市場動態

全球乳癌市場的促進因素

提高認知和早期發現

人們對乳癌的認知和早期檢測的重要性不斷提高，導致人們更多地參與篩檢計劃和定期檢查。政府配合措施、意識提升活動和支持組織在促進早期檢測、促進市場成長方面發揮關鍵作用。

醫療支出增加

醫療保健支出的增加，特別是在已開發國家，正在支持市場的成長。研究與開發、基礎設施開發和先進治療方法方面的投資正在對市場產生積極影響。

全球乳癌市場的抑制因素

個人化醫療的挑戰

乳癌是一種異質性疾病，有不同的亞型和不同的治療反應。開發個體化治療方法並為每位患者確定最合適的治療方法既困難又耗時，限制了精準醫學的普及。

醫療保健差異和獲得治療的機會

獲得醫療保健方面的差異，特別是在低收入地區和服務不足的人群中，是主要障礙。篩檢計劃、診斷設施、專業治療和支持性護理服務的取得機會有限，阻礙了及時診斷和最佳治療，影響了市場成長。

全球乳癌趨勢

標靶治療的興起：標靶治療透過選擇性地針對癌細胞內的特定分子異常，徹底改變了乳癌的治療。 HER2標靶治療，例如單株抗體和酪胺酸激酶抑制劑，顯著改善了HER2陽性乳癌的治療結果。此外，專注於其他分子標靶的新標靶治療，如 PI3K 抑制劑和 CDK4/6 抑制劑，在各種乳癌亞型中顯示出前景。

以病人為中心的方法：市場越來越關注以病人為中心的照護。病患權益倡導者、醫療保健提供者和製藥公司正在共同努力滿足乳癌患者的整體需求。這包括提供支持性護理服務、生存計劃和社會心理支持，以改善患者整個就診過程中的生活品質。

本報告針對全球乳癌市場進行研究和分析，提供市場動態與前景、細分分析、公司簡介等。

Pfizer Inc. - US
Novartis AG - Switzerland
Roche Holding AG - Switzerland
AstraZeneca PLC - UK
Johnson & Johnson - US
Merck & Co., Inc. - US
Bristol Myers Squibb Company - US
Eli Lilly and Company - US
Sanofi - France
AbbVie Inc. - US
Daiichi Sankyo Company, Limited - Japan
Amgen Inc. - US
Genentech, Inc. - US
Takeda Pharmaceutical Company Limited - Japan
Eisai Co., Ltd. - Japan
Mylan NV - US
Celgene Corporation - US
Astellas Pharma Inc. - Japan
Teva Pharmaceutical Industries Ltd. - Israel
Hologic, Inc. - US

簡介目錄

Product Code: SQMIG35D2109

Global Breast Cancer Market size was valued at USD 28.88 Billion in 2021 and is poised to grow from USD 31.89 Billion in 2022 to USD 70.53 Billion by 2030, at a CAGR of 10.43% during the forecast period (2023-2030).

The breast cancer market is driven by the increasing incidence of breast cancer cases globally. Factors such as lifestyle changes, hormonal imbalances, genetic predisposition, and the aging population contribute to the rising number of breast cancer cases. This growing patient population necessitates the development of effective and innovative treatment options and diagnostic tools. Technological advancements play a crucial role in the growth of the breast cancer market. Novel diagnostic techniques, such as molecular imaging, genetic testing, and liquid biopsies, enable early detection and accurate diagnosis of breast cancer. Similarly, advancements in treatment modalities, including targeted therapies, immunotherapies, and precision medicine, have improved patient outcomes and survival rates. These advancements drive the demand for innovative products and therapies in the market. Moreover, the increasing awareness of breast cancer and the importance of early detection among the general population have led to greater participation in screening programs and routine check-ups. Governments and healthcare organizations worldwide have implemented awareness campaigns to promote early detection, resulting in increased demand for screening and diagnostic procedures. Despite the growth prospects, the breast cancer market also faces several challenges. One significant challenge is the high cost associated with breast cancer treatment, including surgery, chemotherapy, radiation therapy, and targeted therapies. The financial burden on patients and healthcare systems can limit access to optimal treatment options, especially in resource-constrained settings.

Top-down and bottom-up approaches were used to estimate and validate the size of the global Breast Cancer Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Breast Cancer Market Segmental Analysis

The global breast cancer market is segmented on the basis of cancer, distribution channel, and region. By cancer, the market is segmented into Hormone Receptor-positive (HR+) and HER2-positive (HER2+) breast cancer. By distribution, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and other channels. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global Breast Cancer Market Dynamics

Drivers of the Global Breast Cancer Market

Growing Awareness and Early Detection

Increased awareness about breast cancer and the importance of early detection have led to higher participation in screening programs and routine check-ups. Government initiatives, awareness campaigns, and advocacy organizations have played a significant role in promoting early detection, contributing to market growth.

Rising Healthcare Expenditure

Increased healthcare spending, particularly in developed economies, has supported the growth of the breast cancer market. Investments in research and development, infrastructure development, and access to advanced treatment modalities have positively impacted the market.

Restraints in the Global Breast Cancer Market

Challenges in Personalized Medicine

Breast cancer is a heterogeneous disease, with different subtypes and variations in treatment response. Developing personalized treatment approaches and identifying the most suitable therapies for each patient can be challenging and time-consuming, limiting widespread adoption of precision medicine.

Healthcare Inequalities and Access to Care

Disparities in healthcare access, particularly in low-income regions and underserved populations, pose a significant restraint. Limited access to screening programs, diagnostic facilities, specialized treatments, and supportive care services can hinder timely diagnosis and optimal treatment, impacting market growth.

Market Trends of the Global Breast Cancer Key

Rise of Targeted Therapies: Targeted therapies have revolutionized breast cancer treatment by selectively targeting specific molecular abnormalities in cancer cells. HER2-targeted therapies, such as monoclonal antibodies and tyrosine kinase inhibitors, have significantly improved outcomes in HER2-positive breast cancer. Additionally, emerging targeted therapies that focus on other molecular targets, such as PI3K inhibitors and CDK4/6 inhibitors, are showing promise in various breast cancer subtypes.

Patient-Centric Approaches: There is a growing emphasis on patient-centered care in the breast cancer market. Patient advocacy groups, healthcare providers, and pharmaceutical companies are working together to address the holistic needs of breast cancer patients. This includes providing supportive care services, survivorship programs, and psychosocial support to improve the quality of life for patients throughout their journey.

Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
- Regulatory Landscape
- Porters Analysis
Competitive rivalry
Threat of Substitute Products
Bargaining Power of Buyers
Threat of New Entrants
Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
Political Impact
Economic Impact
Social Impact
Technical Impact
Environmental Impact
Legal Impact
Global Breast Cancer Market by Cancer
- Market Overview
- Hormone Receptor-positive (HR+) and HER2-positive (HER2+)
Global Breast Cancer Market by Distribution Channel
- Market Overview
- hospital pharmacies
- retail pharmacies
- online pharmacies
- and other channels
Global Breast Cancer Market Size by Region
- Market Overview
- North America
USA
Canada
- Europe
Germany
Spain
France
UK
Rest of Europe
- Asia Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
- Latin America
Brazil
Rest of Latin America
- Middle East & Africa (MEA)
GCC Countries
South Africa
Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
By Development
By Company
By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Pfizer Inc. - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Novartis AG - Switzerland
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Roche Holding AG - Switzerland
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- AstraZeneca PLC - UK
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Johnson & Johnson - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Merck & Co., Inc. - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Bristol Myers Squibb Company - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Eli Lilly and Company - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Sanofi - France
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- AbbVie Inc. - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Daiichi Sankyo Company, Limited - Japan
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Amgen Inc. - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Genentech, Inc. - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Takeda Pharmaceutical Company Limited - Japan
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Eisai Co., Ltd. - Japan
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Mylan N.V. - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Celgene Corporation - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Astellas Pharma Inc. - Japan
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Teva Pharmaceutical Industries Ltd. - Israel
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Hologic, Inc. - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments